Vuorinen V, Heikkonen J, Brander A, Setälä K, Sane T, Randell T, Paetau A, Pohjola J, Mäntylä M, Jääskeläinen J
Department of Neurosurgery, University of Helsinki, Finland.
Acta Neurochir (Wien). 1996;138(5):495-508. doi: 10.1007/BF01411167.
I-125 seeds were permanently implanted into 25 parasellar-clival meningiomas (median age of patients, 56 y) and 19 globoid meningiomas in the elderly (median age of patients, 77 y) using stereotactic technique and 3-D dose planning. Total dose at the tumour margin was increased during the series from 100 Gy to 150 Gy. The procedure caused no mortality and no serious bleeding, but injury to the III cranial nerve due to puncture occurred in one (4%) of the 25 parasellar-clival meningiomas. In two (4.5%) of the 44 cases the postoperative CT scan showed a misplaced seed, located at the tumour surface. Nonenhancing hypodense rings developed around the seeds ('hot spots') with a median diameter of 10.5 mm at 12 months corresponding to a median initial activity of 8.7 mCi. In general, meningiomas responded by slow reduction in volume. The parasellar-clival meningiomas were followed-up for a median of 19 months (6-32), and so far 4 tumours have shrunk moderately, 13 slightly, and 5 not at all. Pre-operative III, V or VI cranial nerve signs were present in 17 patients and subsided in 8 of them. On the other hand, facial numbness developed or increased in 9 of the 25 patients, indicating that the V nerve is rather sensitive to this type of irradiation. In the 19 meningiomas of the elderly, the median follow-up time was 14 months (5-26). The median relative tumour volume was 46% at 12 months. Accounting for tumour-related deaths only, the actuarial survival rate was 78% at 12 months and 62% at 24 months. In general, brain oedema persisted despite reduction in tumour volume. Stereotactic implantation of I-125 seeds into intracranial meningiomas is relatively safe. Interstitial radiotherapy represents a potential tool in the control of medium-sized intracranial meningiomas with minimal brain oedema, but its long-term impact and untoward effects remain to be followed-up.
采用立体定向技术和三维剂量规划,将碘-125粒子永久性植入25例鞍旁-斜坡脑膜瘤患者(患者中位年龄56岁)和19例老年球状脑膜瘤患者(患者中位年龄77岁)体内。在该系列研究中,肿瘤边缘的总剂量从100 Gy增加到150 Gy。该操作未导致死亡和严重出血,但在25例鞍旁-斜坡脑膜瘤中有1例(4%)因穿刺导致Ⅲ颅神经损伤。在44例患者中有2例(4.5%)术后CT扫描显示有1枚粒子位置不当,位于肿瘤表面。粒子(“热点”)周围出现无强化的低密度环,在12个月时中位直径为10.5 mm,对应初始中位活度为8.7 mCi。一般来说,脑膜瘤体积缓慢缩小。鞍旁-斜坡脑膜瘤的中位随访时间为19个月(6 - 32个月),到目前为止,4例肿瘤中度缩小,13例轻度缩小,5例无变化。17例患者术前有Ⅲ、Ⅴ或Ⅵ颅神经体征,其中8例体征消失。另一方面,25例患者中有9例出现面部麻木或加重,表明Ⅴ神经对这种类型的照射相当敏感。在19例老年脑膜瘤患者中,中位随访时间为14个月(5 - 26个月)。12个月时肿瘤相对体积的中位数为46%。仅考虑与肿瘤相关的死亡情况,12个月时精算生存率为78%,24个月时为62%。一般来说,尽管肿瘤体积缩小,但脑水肿仍然存在。将碘-125粒子立体定向植入颅内脑膜瘤相对安全。间质放疗是控制中等大小颅内脑膜瘤且脑水瘤最小的一种潜在手段,但其长期影响和不良效应仍有待随访观察。